Prof. Dr. Melpomeni Fani

Eigler, Christopher, McDougall, Lisa, Bauman, Andreas, Bernhardt, Peter, Hentschel, Michael, Blackham, Kristine A., Nicolas, Guillaume, Fani, Melpomeni, Wild, Damian, & Cordier, Dominik. (2024). Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. Journal of Nuclear Medicine, 65, 573–579. https://doi.org/10.2967/jnumed.123.266817

Fricke, Julia, Westerbergh, Frida, McDougall, Lisa, Favaretto, Chiara, Christ, Emanuel, Nicolas, Guillaume P., Geistlich, Susanne, Borgna, Francesca, Fani, Melpomeni, Bernhardt, Peter, van der Meulen, Nicholas P., Müller, Cristina, Schibli, Roger, & Wild, Damian. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06641-w

Neubauer, Moritz C., Nicolas, Guillaume P., Bauman, Andreas, Fani, Melpomeni, Nitzsche, Egbert, Afshar-Oromieh, Ali, Forrer, Flavio, Rentsch, Cyril, Stenner, Frank, Templeton, Arnoud, Schäfer, Niklaus, Wild, Damian, & Chirindel, Alin. (2024). Early response monitoring during [ 177 Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging, 51, 1185–1193. https://doi.org/10.1007/s00259-023-06536-2

Rottenburger, Christof, Hentschel, Michael, Fürstner, Markus, McDougall, Lisa, Kottoros, Danijela, Kaul, Felix, Mansi, Rosalba, Fani, Melpomeni, Vija, A. Hans, Schibli, Roger, Geistlich, Susanne, Behe, Martin, Christ, Emanuel R., & Wild, Damian. (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [ 177 Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Research, 14. https://doi.org/10.1186/s13550-024-01101-w

Fani, Melpomeni, & Nicolas, Guillaume P. (2023). ⁶¹Cu-labeled radiotracers: Alternative or choice? Journal of Nuclear Medicine, 64, 1855–1857. https://doi.org/10.2967/jnumed.123.266171

Gaonkar, Raghuvir Haridas, Schmidt, Yannik Tim, Mansi, Rosalba, Almeida-Hernandez, Yasser, Sanchez-Garcia, Elsa, Harms, Mirja, Münch, Jan, & Fani, Melpomeni. (2023). Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications. Journal of Medicinal Chemistry, 66, 8484–8497. https://doi.org/10.1021/acs.jmedchem.3c00131

Grand-Guillaume, Joana, Mansi, Rosalba, Gaonkar, Raghuvir H., Zanger, Sandra, Fani, Melpomeni, Eugster, Philippe J., Beck Popovic, Maja, Grouzmann, Eric, & Abid, Karim. (2023). CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (^123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors. Journal of Translational Medicine, 21. https://doi.org/10.1186/s12967-023-04466-z

Millul, Jacopo, Koepke, Lennart, Haridas, Gaonkar Raghuvir, Sparrer, Konstantin M. J., Mansi, Rosalba, & Fani, Melpomeni. (2023). Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides [Journal-article]. European Journal of Nuclear Medicine and Molecular Imaging, 50(10), 3050–3061. https://doi.org/10.1007/s00259-023-06272-7

Novak, Doroteja, Janota, Barbara, Hörmann, Anton Amadeus, Sawicka, Agnieszka, Kroselj, Marko, Hubalewska-Dydejczyk, Alicja, Fani, Melpomeni, Mikolajczak, Renata, Kolenc, Petra, Decristoforo, Clemens, & Garnuszek, Piotr. (2023). Development of the ^99mTc-Labelled SST<inf>2</inf> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics, 15. https://doi.org/10.3390/pharmaceutics15030885

Opalinska, Marta, Lezaic, Luka, Decristoforo, Clemens, Kolenc, Petra, Mikolajczak, Renata, Studen, Andrej, Simoncic, Urban, Virgolini, Irene, Trofimiuk-Muldner, Malgorzata, Garnuszek, Piotr, Rangger, Christine, Fani, Melpomeni, Glowa, Boguslaw, Skorkiewicz, Konrad, & Hubalewska-Dydejczyk, Alicja. (2023). Comparison of 99mTc radiolabeled somatostatin antagonist with [⁶⁸ Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging, 50, 4110–4111. https://doi.org/10.1007/s00259-023-06335-9

Wild, Damian, & Fani, Melpomeni. (2023). Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy. In Radiopharmaceutical Therapy (pp. 335–348). Springer International Publishing. https://doi.org/10.1007/978-3-031-39005-0_16

Fani, Melpomeni, Mansi, Rosalba, Nicolas, Guillaume P., & Wild, Damian. (2022). Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals. Cancers, 14(5). https://doi.org/10.3390/cancers14051172

Refardt J, Hofland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, & Christ E. (2021). Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Reviews in Endocrine & Metabolic Disorders, 22(3), 581–594. https://doi.org/10.1007/s11154-020-09552-x

Wild D, Antwi K, Fani M, & Christ ER. (2021). Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 62(Suppl 2), 44S–50S. https://doi.org/10.2967/jnumed.120.246009

Mansi R, & Fani M. (2021). Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside. Chimia, 75(6), 500–504. https://doi.org/10.2533/chimia.2021.500

Gaonkar RH, Wiesmann F, Del Pozzo L, McDougall L, Zanger S, Mikołajczak R, Mansi R, & Fani M. (2021). SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. Pharmaceuticals (Basel, Switzerland), 14(4). https://doi.org/10.3390/ph14040300

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, et al. (2021). Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer (Oxford, England : 1990), 146, 56–73. https://doi.org/10.1016/j.ejca.2021.01.008

Mansi, Rosalba, Plas, Pascale, Vauquelin, Georges, & Fani, Melpomeni. (2021). Distinct in vitro binding profile of the somatostatin receptor subtype 2 antagonist [¹⁷⁷ lu]lu-ops201 compared to the agonist [¹⁷⁷ lu]lu-dota-tate. Pharmaceuticals, 14. https://doi.org/10.3390/ph14121265

Fani M, Weingaertner V, Kolenc Peitl P, Mansi R, Gaonkar RH, Garnuszek P, Mikolajczak R, Novak D, Simoncic U, Hubalewska-Dydejczyk A, Rangger C, Kaeopookum P, & Decristoforo C. (2020). Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals (Basel, Switzerland), 14(1). https://doi.org/10.3390/ph14010019

Mansi R, Nicolas GP, Del Pozzo L, Abid KA, Grouzmann E, & Fani M. (2020). Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5. Molecules (Basel, Switzerland), 25(18). https://doi.org/10.3390/molecules25184155

Antwi K, Hepprich M, Müller NA, Reubi JC, Fani M, Rottenburger C, Nicolas G, Kaul F, Christ ER, & Wild D. (2020). Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clinical Nuclear Medicine, 45(9), e386–e392. https://doi.org/10.1097/rlu.0000000000003124

Mansi R, Abid K, Nicolas GP, Del Pozzo L, Grouzmann E, & Fani M. (2020). A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting. EJNMMI Research, 10(1), 90. https://doi.org/10.1186/s13550-020-00677-3

Christ E, Antwi K, Fani M, & Wild D. (2020). Innovative imaging of insulinoma: the end of sampling? A review. Endocrine-Related Cancer, 27(4), R79–R92. https://doi.org/10.1530/erc-19-0476

Coto-Llerena, Mairene, Ercan, Caner, Kancherla, Venkatesh, Taha-Mehlitz, Stephanie, Eppenberger-Castori, Serenella, Soysal, Savas D., Ng, Charlotte K. Y., Bolli, Martin, von Flüe, Markus, Nicolas, Guillaume P., Terracciano, Luigi M., Fani, Melpomeni, & Piscuoglio, Salvatore. (2020). High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Frontiers in Oncology, 10, 979. https://doi.org/10.3389/fonc.2020.00979

Antwi K, Nicolas G, Fani M, Heye T, Pattou F, Grossman A, Chanson P, Reubi JC, Perren A, Gloor B, Vogt DR, Wild D, & Christ E. (2019). 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. The Journal of Clinical Endocrinology and Metabolism, 104(12), 5843–5852. https://doi.org/10.1210/jc.2018-02754

Mansi R., & Fani M. (2019). Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors. Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), 635–645. https://doi.org/10.1002/jlcr.3755

Antwi K, Nicolas G, Fani M, Christ E, & Wild D. (2019). Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT. Clinical Nuclear Medicine, 44(5), e347–e348. https://doi.org/10.1097/rlu.0000000000002522

Beykan S, Fani M, Jensen SB, Nicolas G, Wild D, Kaufmann J, & Lassmann M. (2019). In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry. Contrast Media & Molecular Imaging, 2019, 6438196. https://doi.org/10.1155/2019/6438196

Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, & Fani M. (2019). Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177 Lu-DOTA-PP-F11N: Does the use of protease inhibitors further improve in vivo distribution? Journal of Nuclear Medicine, 60(3), 393–399. https://doi.org/10.2967/jnumed.118.207845

Nicolas GP, Morgenstern A, Schottelius M, & Fani M. (2018). New Developments in Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.118.213496

Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, Merkle E, Zech CJ, Boll D, Vogt DR, Gloor B, Christ E, & Wild D. (2018). Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2318–2327. https://doi.org/10.1007/s00259-018-4101-5

Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, & Wild D. (2018). Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(6), 909–914. https://doi.org/10.2967/jnumed.117.199737

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, & Wild D. (2018). Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(6), 915–921. https://doi.org/10.2967/jnumed.117.199760

Nock B.A., Charalambidis D., Sallegger W., Waser B., Mansi R., Nicolas G.P., Ketani E., Nikolopoulou A., Fani M., Reubi J.-C., & Maina T. (2018). New Gastrin Releasing Peptide Receptor-Directed [ 99m Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation. Journal of Medicinal Chemistry, 61(7), 3138–3150. https://doi.org/10.1021/acs.jmedchem.8b00177

Nicolas GP, Wild D, & Fani M. (2018). Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. (Patent No. 3). 59(3), Article 3. https://doi.org/10.2967/jnumed.117.203703

Abiraj, Keelara, Ursillo, Samer, Tamma, Maria Luisa, Rylova, Svetlana N., Waser, Beatrice, Constable, Edwin C., Fani, Melpomeni, Nicolas, Guillaume P., Reubi, Jean Claude, & Maecke, Helmut R. (2018). The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. EJNMMI Research, 8, 75. https://doi.org/10.1186/s13550-018-0428-y

Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, & Maecke HR. (2018). The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PloS one, 13(4), e0195802. https://doi.org/10.1371/journal.pone.0195802

Fani M, Nicolas GP, & Wild D. (2017). Somatostatin Receptor Antagonists for Imaging and Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(Suppl 2), 61S–66S. https://doi.org/10.2967/jnumed.116.186783

Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, & Fani M. (2017). Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(9), 1435–1441. https://doi.org/10.2967/jnumed.117.191684

Fani M, Peitl PK, & Velikyan I. (2017). Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals (Basel, Switzerland), 10(1). https://doi.org/10.3390/ph10010030

Melpomeni,Fani. (2017). Current and Future Radiopharmaceuticals in Neuroendocrine Tumor Imaging (pp. 141–162). https://doi.org/10.1007/978-3-319-46038-3_7

Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Baer HU, Perren A, & Reubi JC. (2015). Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT. Endocrine, 50(3), 821–823. https://doi.org/10.1007/s12020-015-0633-7

Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, & Wild D. (2015). Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 56(7), 1075–1078. https://doi.org/10.2967/jnumed.115.157768

Wenning AS, Kirchner P, Antwi K, Fani M, Wild D, Christ E, & Gloor B. (2015). Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases. Patient Safety in Surgery, 9, 23. https://doi.org/10.1186/s13037-015-0064-7

Christ,Emanuel, Wild,Damian, Antwi,Kwadwo, Waser,Beatrice, Fani,Melpomeni, Schwanda,Stefanie, Heye,Tobias, Schmid,Christoph, Baer,Hans Ulrich, Perren,Aurel, & Reubi,Jean Claude. (2015). Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT. Endocrine, 50(3), 821–823.

Fani,Melpomeni, & Maecke,Helmut R. (2015). Radiolabeled Somatostatin Receptor Antagonists. In John Wiley & Sons Inc. (Vol. 8, pp. 306–321).

Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, Maecke HR, & Weber WA. (2014). Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(11), 1878–1884. https://doi.org/10.2967/jnumed.114.137570

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, & Weber WA. (2014). Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 55(8), 1248–1252. https://doi.org/10.2967/jnumed.114.138834

Bouziotis P, Gourni E, Patsis G, Psimadas D, Zikos C, Fani M, Xanthopoulos S, Loudos G, Paravatou-Petsotas M, Livaniou E, Varvarigou AD, Pirmettis I, & Papadopoulos M. (2013). Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the (99m)Tc(CO)3(+) core. Bioorganic & medicinal chemistry, 21(21), 6699–6707. https://doi.org/10.1016/j.bmc.2013.08.010

Leonhardt F, Grundmann S, Behe M, Bluhm F, Dumont RA, Braun F, Fani M, Riesner K, Prinz G, Hechinger AK, Gerlach UV, Dierbach H, Penack O, Schmitt-Gräff A, Finke J, Weber WA, & Zeiser R. (2013). Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. Blood, 121(17), 3307–3318. https://doi.org/10.1182/blood-2012-07-442665

Wang X, Fani M, Schulz S, Rivier J, Reubi JC, & Maecke HR. (2012). Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European journal of nuclear medicine and molecular imaging, 39(12), 1876–1885. https://doi.org/10.1007/s00259-012-2231-8

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, & Reubi JC. (2012). Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(9), 1481–1489. https://doi.org/10.2967/jnumed.112.102764

Fani M, Tamma ML, Nicolas GP, Lasri E, Medina C, Raynal I, Port M, Weber WA, & Maecke HR. (2012). In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Molecular pharmaceutics, 9(5), 1136–1145. https://doi.org/10.1021/mp200418f

Psimadas D, Fani M, Gourni E, Loudos G, Xanthopoulos S, Zikos C, Bouziotis P, & Varvarigou AD. (2012). Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical. Bioorganic & medicinal chemistry, 20(8), 2549–2557. https://doi.org/10.1016/j.bmc.2012.02.051

Fani, Melpomeni, & Maecke, Helmut R. (2012). Radiopharmaceutical development of radiolabelled peptides. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 39, 11–30. https://doi.org/10.1007/s00259-011-2001-z

Fani M, Maecke HR, & Okarvi SM. (2012). Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics, 2(5), 481–501. https://doi.org/10.7150/thno.4024

Cescato R, Waser B, Fani M, & Reubi JC. (2011). Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(12), 1886–1890. https://doi.org/10.2967/jnumed.111.095778

Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, Maecke HR, & Weber WA. (2011). First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(9), 1412–1417. https://doi.org/10.2967/jnumed.111.088922

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, & Fani M. (2011). Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(8), 1276–1284. https://doi.org/10.2967/jnumed.111.087700

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, Waser B, Weber WA, Reubi JC, & Maecke HR. (2011). PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(7), 1110–1118. https://doi.org/10.2967/jnumed.111.087999

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C, & Haubner R. (2011). [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. European journal of nuclear medicine and molecular imaging, 38(7), 1303–1312. https://doi.org/10.1007/s00259-011-1778-0

Abiraj, Keelara, Mansi, Rosalba, Tamma, Maria-Luisa, Fani, Melpomeni, Forrer, Flavio, Nicolas, Guillaume, Cescato, Renzo, Reubi, Jean Claude, & Maecke, Helmut R. (2011). Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Journal of Nuclear Medicine, 52(12), 1970–1978. https://doi.org/10.2967/jnumed.111.094375

Ambrosini, Valentina, Fani, Melpomeni, Fanti, Stefano, Forrer, Flavio, & Maecke, Helmut R. (2011). Radiopeptide imaging and therapy in Europe. Journal of Nuclear Medicine, 52 Suppl 2, 42S–55S. https://doi.org/10.2967/jnumed.110.085753

Fani M, Wang X, Nicolas G, Medina C, Raynal I, Port M, & Maecke HR. (2011). Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates. European Journal of Nuclear Medicine and Molecular Imaging, 38(1), 108–119. https://doi.org/10.1007/s00259-010-1597-8

Fani,Melpomeni, Good,S., & Maecke,Helmut R. (2011). Radiometals (non-Tc, non-Re) and Bifunctional Labeling Chemistry (Vol. 45, pp. 2143–2178).

Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, Reubi JC, & Maecke HR. (2010). Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 51(11), 1771–1779. https://doi.org/10.2967/jnumed.110.076695

Forrer, Flavio, Chen, Jianhua, Fani, Melpomeni, Powell, Pia, Lohri, Andreas, Müller-Brand, Jan, Moldenhauer, Gerhard, & Maecke, Helmut R. (2009). In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. European Journal of Nuclear Medicine and Molecular Imaging, 36(9), 1443–1452. https://doi.org/10.1007/s00259-009-1120-2

Fani, Melpomeni, André, João P, & Maecke, Helmut R. (2008). 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media & Molecular Imaging, 3(2), 67–77. https://doi.org/10.1002/cmmi.232

Fani M., Bouziotis P., Harris A.L., Psimadas D., Gourni E., Loudos G., Varvarigou A.D., & Maecke H.R. (2007). ¹⁷⁷Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems. Radiochimica Acta, 95(6), 351–357. https://doi.org/10.1524/ract.2007.95.6.351

Bouziotis, P., Psimadas, D., Fani, M., Gourni, E., Loudos, G., Xanthopoulos, S., Archimandritis, S. C., & Varvarigou, A. D. (2006). Radiolabeled biomolecules for early cancer detection and therapy via angiogenesis targeting. 569, 492–496. https://doi.org/10.1016/j.nima.2006.08.142

Gourni, Eleni, Bouziotis, Penelope, Zikos, Christos, Loudos, George, Xanthopoulos, Stavros, Fani, Melpomeni, Archimandritis, Spyridon C., & Varvarigou, Alexandra D. (2006). Comparative in vivo evaluation of two novel Tc-99m labelled bombesin derivatives. 569, 518–521. https://doi.org/10.1016/j.nima.2006.08.141

Fani M, Psimadas D, Zikos C, Xanthopoulos S, Loudos GK, Bouziotis P, & Varvarigou AD. (2006). Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer research, 26(1A), 431–434.

Gourni E, Paravatou M, Bouziotis P, Zikos C, Fani M, Xanthopoulos S, Archimandritis SC, Livaniou E, & Varvarigou AD. (2006). Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detection. Anticancer research, 26(1A), 435–438.

Fani,M., & Maecke,H.R. (2006). The status of diagnostic and therapeutic targeting of somatostatin receptor-positive tumors. In SGE Ditoriali Padova: Vol. - (pp. 263–276).

Psimadas,D, Fani,M, Zikos,C, Xanthopoulos,S, Archimandritis,S C, & Varvarigou,A D. (2006). Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3(CO)3]+ and evaluation for early angiogenesis detection in cancer. Appl Radiat Isotopes (Print-Ausgabe), 64(9), 151–159.

Bouziotis P, Fani M, Archimandritis SC, Loundos G, Paravatou M, Bicknell R, Harris AL, Xanthopoulos S, Stratis N, & Varvarigou AD. (2003). Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition. Anticancer research, 23(3A), 2167–2171.

Fani M, Xanthopoulos S, Archimandritis SC, Stratis N, Bouziotis P, Loudos G, & Varvarigou AD. (2003). Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy. Anticancer research, 23(3A), 2195–2199.

Fani M, Vranjes S, Archimandritis SC, Potamianos S, Xanthopoulos S, Bouziotis P, & Varvarigou AD. (2002). Labeling of monoclonal antibodies with 153Sm for potential use in radioimmunotherapy. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 57(5), 665–674. https://doi.org/10.1016/s0969-8043(02)00181-1